NASDAQ:CLDX

Celldex Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CLDX

*Your capital is at risk

$29.77

+0.87 (+3.01%)

At Close: Jun 03, 2026

Celldex Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 45.48. In total, the insiders bought 4.45M and sold 170.35K CLDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	45.48
● Buy	4.45M shares
● Sell	170.35K shares
88% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Jun 01, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 45.48. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (88% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 05, 2025 Buy	Incentive Stock Option (right to buy) A-Award	Jimenez Freddy A. SVP & General Counsel	Officer	75 000 Value: $1.46M
Jun 05, 2025 Buy	Incentive Stock Option (right to buy) A-Award	Heath-chiozzi Margo SVP Of Regulatory Affairs	Officer	82 000 Value: $1.60M
Jun 05, 2025 Buy	Incentive Stock Option (right to buy) A-Award	Crowley Elizabeth Sr. Vp & Cpdo	Officer	85 000 Value: $1.66M
Jun 05, 2025 Buy	Incentive Stock Option (right to buy) A-Award	Cavanaugh Sarah SVP Of Corp Affairs & Admin.	Officer	78 000 Value: $1.52M
Jun 05, 2025 Buy	Common Stock J-Other	Torres Denice	Director	0 Value: $0
Jun 05, 2025 Buy	Common Stock J-Other	Torres Denice	Director	0 Value: $0
Nov 18, 2024 Sell	Common Stock G-Gift	Marino James J Director	Director	10 500 Value: $0
Nov 18, 2024 Sell	Common Stock G-Gift	Marino James J Director	Director	10 500 Value: $0
Nov 11, 2024 Buy	Common Stock P-Purchase	Marucci Anthony S President & CEO	CEO / President	11 500 Value: $308.4K
Nov 11, 2024 Buy	Common Stock P-Purchase	Marucci Anthony S President & CEO	CEO / President	11 500 Value: $308.4K
Jun 14, 2024 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	16 968 Value: $176.1K
Jun 14, 2024 Buy	Common Stock M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	16 968 Value: $176.1K
Jun 14, 2024 Buy	Common Stock M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	3 201 Value: $28.9K
Jun 14, 2024 Sell	Common Stock S-Sale	Martin Samuel Bates SVP And CFO	C-Suite Officer	17 172 Value: $608.3K
Jun 14, 2024 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	3 201 Value: $28.9K
Jun 14, 2024 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $311.4K
Jun 14, 2024 Buy	Common Stock M-Exempt	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $311.4K
Jun 14, 2024 Sell	Common Stock S-Sale	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $1.05M
Jun 14, 2024 Sell	Common Stock S-Sale	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $1.05M
Jun 14, 2024 Buy	Common Stock M-Exempt	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $311.4K
Jun 14, 2024 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Crowley Elizabeth Sr. Vp & Cpdo	Officer	30 000 Value: $311.4K
Jun 14, 2024 Buy	Incentive Stock Option (Right to Buy) M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	3 201 Value: $28.9K
Jun 14, 2024 Sell	Common Stock S-Sale	Martin Samuel Bates SVP And CFO	C-Suite Officer	17 172 Value: $608.3K
Jun 14, 2024 Buy	Common Stock M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	3 201 Value: $28.9K
Jun 14, 2024 Buy	Common Stock M-Exempt	Martin Samuel Bates SVP And CFO	C-Suite Officer	16 968 Value: $176.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CELLDEX THERAPEUTICS

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...

Read Full Profile Here